DAPT (GSI-IX) is a potent and orally active gamma-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-beta (Abeta) and Abeta42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment[1][2].
